# A Single and Multiple-Dose Study of MK-8521 in Healthy and Obese Males (MK-8521-002)

> **NCT02055547** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 61 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** MK-8521 35μg
- **DRUG:** MK-8521 100μg
- **DRUG:** MK-8521 125μg
- **DRUG:** MK-8521 150μg
- **DRUG:** MK-8521 175μg
- **DRUG:** MK-8521 200μg
- **DRUG:** MK-8521 300μg
- **DRUG:** MK-8521 50/72μg
- **DRUG:** MK-8521 72/125μg
- **DRUG:** MK-8521 100/150μg
- **DRUG:** MK-8521 125/150μg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02055547
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05-10
- **Primary completion:** 2013-09-17
- **Final completion:** 2013-09-17
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2020-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02055547

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02055547, "A Single and Multiple-Dose Study of MK-8521 in Healthy and Obese Males (MK-8521-002)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02055547. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*